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Abstract
Background: Tumour metastasis remains the major cause of death in cancer patients and, to date, the mechanism
and signalling pathways governing this process are not completely understood. The TGF-β pathway is the most
commonly mutated pathway in cancer, however its role in cancer progression is controversial as it can function as
both a promoter and a suppressor of metastasis. Although previous studies have suggested a role for the molecular
chaperone Hsp90 in regulating the TGF-β pathway, the level at which this occurs as well as the consequences in
terms of colon cancer metastasis are unknown.
Methods: The paired SW480 and SW620 colon cancer cell lines, derived from a primary tumour and its lymph node
metastasis, respectively, were used as an in vitro model to study key cellular processes required for metastasis. The
status of the TGF-β pathway was examined in these cells using ELISA, flow cytometry, western blot analysis and
confocal microscopy. Furthermore, the effect of addition or inhibition of the TGF-β pathway and Hsp90 on adhesion,
migration and anchorage-independent growth, was determined in the cell lines.
Results: When comparing the canonical TGF-β1 pathway in the genetically paired cell lines our data suggests that this
pathway may be constitutively active in the SW620 metastasis-derived cell line and not the SW480 primary tumour-
derived line. In addition, we report that, when present in combination, TGF-β1 and Hsp90β stimulate anchorage-
independent growth, reduce adhesion and stimulate migration. This effect is potentiated by inhibition of the TGF-β1
receptor and occurs via an alternate TGF-β1 pathway, mediated by αvβ6 integrin. Interestingly, in the SW620 cells,
activation of this alternate TGF-β1 signalling machinery does not appear to require inhibition of the canonical TGF-β1
receptor, which would allow them to respond more effectively to the pro-metastasis stimulus of a combination of
Hsp90β and TGF-β1 and this could account for the increased migratory capacity of these cells.
Conclusions: In this study we report an apparent synergy between TGF-β1 and Hsp90β in stimulating migratory
behaviour of colon cancer cells when signalling occurs via αvβ6 integrin as opposed to the canonical TGF-β1 pathway.
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Background
According to the latest available statistics, colorectal can-
cer is the second highest cause of cancer related deaths in
the USA [1]. A potential reason for this high fatality rate is
the fact that this form of the disease is highly metastatic
[2, 3]. Despite the fact that the mechanisms underlying
tumour metastasis have been a major focus in cancer re-
search in recent years, the spread of cancers to second-
ary sites in the body remains the leading cause of
mortality [3, 4].
The “seeds and soil” theory of metastasis proposed by
Paget over a century ago, suggests that metastasis is
dependent on characteristics of both the migrating tumour
cells (seeds) and the local environment (soil) [5]. The
microenvironment refers to the complex milieu surround-
ing tumour cells and is composed of a unique combination
of non-cancerous cells including fibroblasts, endothelial
and various immune cells as well as chemical messengers
in the form of cytokines and chemokines [6]. There is a
growing appreciation of the role of the microenvironment,
the “soil” in Paget’s theory of metastasis, in the develop-
ment and spread of cancers as evidenced by the expo-
nential increase in the number of research articles on
this topic in recent years [7].
Of particular interest to this study, the microenviron-
mental niche element transforming growth factor-β
(TGF-β) has been found to represent the most com-
monly altered signalling pathway in cancer [8–10]. The
TGF-β superfamily consists of a number of related li-
gands, namely TGF-β1, TGF-β2, TGF-β3, bone mor-
phogenetic proteins (BMP), activin, nodal and growth
and differentiation factors (GDFs) each with specific re-
ceptor affinities. In the canonical TGF-β pathway, the
TGF-β1 ligand binds to the type II receptor (TGF-βRII)
which then recruits the type I receptor (TGF-βRI) forming
a heterodimeric complex which stimulates receptor-
associated protein kinase activity [11, 12]. This phosphory-
lates the transcription factors Smad2 and Smad3, resulting
in the binding of Smad2 and Smad3 to Smad4. This
complex translocates into the nucleus where it regulates
the expression of a large cohort of genes responsible for
controlling key cellular processes such as proliferation,
differentiation and survival [12]. Although TGF-β has
been implicated in colon cancer metastasis [13], the exist-
ing data is contradictory and controversial, with some
groups claiming that the protein inhibits metastasis [14],
while others report that it promotes metastasis [15].
Tumour cells, particularly migrating cells, are exposed
to a variety of physiological stresses and produce an
accumulation of overexpressed and mutated proteins
requiring an upregulation of molecular chaperones in
order to overcome these stresses [16]. One such
chaperone is heat shock protein 90 (Hsp90) which has
also been referred to as the cancer chaperone due to
its large cohort of oncogenic client proteins and 2-10
fold upregulation in cancer cells [17]. Hsp90 is a drug
target with a number of inhibitors targeting this pro-
tein in clinical trials [18, 19]. The chaperone has two
cytosolic isoforms; Hsp90α, which is inducible yet non-
essential in the mouse and Hsp90β, the constitutive
and essential isoform of the protein [20, 21]. The vast
majority of studies regarding the role of Hsp90 in can-
cer biology have been carried out in the intracellular
compartments of the cell [22]. In the last decade, how-
ever, Hsp90 has increasingly been found to activate
signalling pathways outside the cell, on the cell surface
facing the extracellular space and in the extracellular
media [21, 23–30]. Hsp90β has been shown to negatively
regulate TGF-β activation in the extracellular space of
osteosarcoma cells in vitro by binding to the latency-
associated peptide (LAP) of inactive TGF-β, while itself
being upregulated by active TGF-β, resulting in a negative
feedback loop [29]. In addition, it has been reported that
Hsp90 regulates TGF-β signalling by binding directly to
both receptors, TGF-βRI and TGF-βRII, preventing their
degradation in non-malignant human cells [31].
Extracellular TGF-β and Hsp90 both stimulate migration
of cancer cells [30, 32–35], however a synergy between
these two proteins in modulating in vitro processes linked
to metastasis has not been demonstrated despite the fact
that they bind common receptors [31].
Methods
Reagents
Leibovitz’s L-15 medium with GlutaMAX™, 10 x Trypsin-
Ethylenediaminetetraacetic acid (EDTA), Penicillin/
Streptomycin/Amphotericin (PSA) solution and Hoescht-
33342 dye were from Gibco, Invitrogen. Heat-inactivated
fetal bovine serum (FBS) was from Celtic Molecular
Diagnostics and Epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF) and Accutase® were
purchased from Sigma-Aldrich. Insulin was obtained
from NovoRapid (Novo Nordisk Pharmaceuticals). Hybond
nitrocellulose membrane and Clarity Western Enhanced
Chemiluminescence [ECL] substrate was from Bio-Rad
(UK). Protein A/G PLUS-Agarose (sc-2003) was from
Santa Cruz Biotechnology (USA). SB431542 (1614) was
from Tocris Bioscience, while 3,3’, 5,5’ Tetramethyl-
benzidine (TMB) substrate, dimethyl sulfoxide (DMSO),
novobiocin (N1838), 5-fluorouracil (5-FU) and oxaliplatin
were from Sigma-Aldrich. Recombinant native endotoxin-
free human Hsp90β protein (SPR-102C) was from Stress-
Marq Biosciences Inc., while recombinant endotoxin-free
human TGF-β1 (carrier-free) (580704) was from BioLe-
gend and bovine serum albumin (BSA) (10735078001)
was from Roche. Mouse anti-human Hsp90α/β [F-8]
(sc-13119), goat anti-human Hsp90α/β [N17] (sc-1055),
HRP-conjugated donkey anti-mouse (sc-2314), mouse
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anti-human TGF-β1 [500-M66] (sc-65378), goat anti-
human p-Smad2/3 (Ser 423/425) (sc-11769) and rabbit
anti-human Smad2/3 (sc-8332) antibodies were from
Santa Cruz. The Alexa-Fluor-550 conjugated donkey
anti-rat (A21208) antibody was from Invitrogen, while
the HRP-conjugated mouse anti-alpha tubulin (ab40742)
and Alexa-Fluor-550 conjugated donkey anti-mouse
(ab96876), donkey anti-rabbit IgG DyLight 550 (DY550)
(ab96892), donkey anti-goat IgG DY660 (ab96934) and
anti-human αvβ6 integrin (ab77906) antibodies were from
Abcam. The fluorescein isothiocyanate (FITC)-conjugated
mouse anti-human TGF-βRII (FAB241F) antibody was
from R&D systems and the rat anti-human Hsp90α anti-
body (ADI-SPA-840-F) was from Enzo Life Sciences. The
mouse anti-human Hsp90β (SMC-107A) antibody was
from StressMarq Biosciences Inc. and the rabbit anti-
histone H3 (sc-10809) antibody was from Cell Signaling
Technologies. The FITC-conjugated mouse IgG1 iso-
type control was from BD Biosciences. The MTT Cell
Proliferation kit 1 was from Roche.
Cell lines
The paired colon cancer cell lines SW480 (ECACC:
87092801, colon adenocarcinoma) and SW620 (ECACC:
87051203, lymph node metastasis) were purchased from
the European Collection of Cell Cultures (ECACC) and
maintained in L-15 Medium with GlutaMAX™ supple-
mented with 10% [v/v] fetal calf serum (Lonza) and
100 U/ml Penicillin, 100 μg/ml Streptomycin and
12.5 μg/ml Amphotericin at 37 °C in a humidified in-
cubator without the introduction of CO2.
Sodium Dodecyl Sulphate-Polyacrylamide Gel
Electrophoresis (SDS PAGE) and Western blot analysis
Unless stated otherwise, whole cell lysates were prepared
from confluent 6-well plates (Nunc) by scraping into lysis
buffer (0.05 M Tris-HCl, 10% [v/v] glycerol, 2% [w/v] SDS).
The total protein content of cell lysates was determined
using a NanoDrop 2000™ spectrophotometer (Thermo
Scientific). The method described by Laemmli (1970)
[36] was used to separate proteins by denaturing electro-
phoresis according to size. Western blotting was per-
formed according to Towbin et al. (1979) [37]. Proteins
were visualised using Clarity Western Enhanced Chemilu-
minescence [ECL] substrate and detected using the
ChemiDoc™ XRS+ system (Bio-Rad) or the film exposure
method (Agfa HealthCare). Where relevant, lysates were
probed for histone H3 (rabbit ant-histone H3) or tubulin
(mouse anti-alpha tubulin) as a loading control.
Confocal microscopy
Gelatin (5% [w/v]) was used to coat 15-well μ-Slide
angiogenesis plates (81506, Ibidi). SW480 and SW620
cells were seeded onto μ-Slide plates and fixed with
methanol and incubated with appropriate primary anti-
bodies followed by the respective secondary antibodies
as described in figure legends. Nuclei were stained with
1 μg/ml Hoechst-33342 dye, after which Dako mounting
medium was added to each well. Immunofluorescence
was detected using the Zeiss LSM 780 laser scanning
confocal microscope and the images analysed using Zen
Lite Software 2012 (Zeiss). Images were captured using
the 63x oil objective. Colocalisation between the nucleus
and pSMAD2/3 staining was performed using the Image
J colocalisation plug-in (National Institutes of Health).
The proportion of total pSMAD2/3 that is found in the
nucleus was determined by developing profiles of the in-
tensity of pSMAD2/3 in a line through the cells using
Zen Lite Software.
Enzyme-linked Immunosorbent Assays (ELISAs)
Cells were seeded into 6-well plates and allowed to ad-
here overnight. The spent media was removed and
centrifuged to remove cell debris. A human TGF-β1
DuoSet Development ELISA kit (R&D Systems Inc.)
was utilised to analyse the expression of TGF-β1 in the
cell culture supernatant (spent media) of the SW480 and
SW620 cell lines. This was carried out according to manu-
facturer’s specifications. Samples of spent medium were
assayed in triplicate and the concentration of TGF-β1 de-
termined from a standard curve generated by assaying
purified recombinant human TGF-β1 diluted to an eight-
point range between 0 pg/ml and 2000 pg/ml in duplicate.
Hsp90β secretion by cells was determined by ELISA from
spent media according to Hunter et al., (2014) [26].
Briefly, spent media or pure protein in buffer A (20 mM
Tris-HCl, 150 mM NaCl, pH 7.4, 1 mM ATP, 5 mM
CaCl2, 0.05% [v/v] Tween 20) was incubated in a high
binding 96-well microplate (655061, Greiner Bio-One,
UK) overnight. Wells were blocked with 3% (w/v) bovine
serum albumin (BSA) in buffer A for 1 h and washed with
1% (w/v) BSA in buffer A, before incubating with mouse
anti-Hsp90β in buffer A (1:1000) for 2 h. After further
washing, incubation with rabbit anti-mouse IgG-HRP sec-
ondary antibody in buffer A (1:10 000) was carried out for
1 h. Detection was carried out using TMB substrate (in
0.05 M Phosphate-Citrate Buffer [0.2 M Na2HPO4, 0.1 M
citric acid, pH 5.0] with 2 μl of 30% [v/v] hydrogen perox-
ide) and quantification was carried out from a standard
curve using recombinant Hsp90β at a six point concentra-
tion range from 0 to 500 ng/ml.
Surface staining of cells for flow cytometry
Cells were harvested using Accutase® solution (Sigma-
Aldrich), collected by centrifugation and resuspended to
a final concentration of 5 × 106 cells/ml. Thereafter 1 μg
fluorescein isothiocyanate (FITC)-conjugated mouse anti-
human TGF-βRII antibody was added to 1 × 106 cells and
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incubated at 4 °C for 1 h in the dark. The stained cell
suspension was washed, collected by centrifugation and
resuspended in phosphate-buffered saline. The stained
cells were analysed using the 488 nm laser of a FACSAria™
III flow cytometer (BD Biosciences) using wavelengths of
488 nm and 519 nm for excitation and emission, respect-
ively. A FITC-conjugated mouse IgG1 isotype control was
used to account for any non-specific binding of primary
antibodies. A further negative control without primary
antibody was used to assess cell autofluorescence. Data
was analysed using FlowJo software version 10.0.4 (Tree
Star Inc., 2013).
Crystal violet adhesion assay
SW480 and SW620 cells were seeded at a density of
1.2 x 105 cells/well into a 96-well plate and treated
with combinations of TGF-β1, Hsp90β, SB431542, novo-
biocin and αvβ6 integrin blocking antibody as indicated in
figure legends. The cells were left to adhere for 8 h at
37 °C before removing the media and washing the wells
with PBS three times. Adherent cells were fixed with
4% [v/v] paraformaldehyde in PBS before washing with
deionised water and staining with 10% [w/v] crystal violet
in 5% [v/v] ethanol. Wells were again washed with deio-
nised water, allowed to air-dry and crystal violet dye
solubilised in 5% [w/v] SDS and 1% [v/v] Triton-X100.
Absorbance was read at 590 nm using a microtitre plate
reader (PowerWaveXTM, BioTek).
Migration assay
SW480 and SW620 cells were seeded at a density of
1.2 x 104 cells into each individual well of a micro-insert
4-well chamber (80409, Ibidi) and left to adhere overnight.
Each insert was filled with L-15 medium containing com-
binations of TGF-β1, Hsp90β, SB431542, novobiocin or
an αvβ6 integrin blocking antibody as indicated in figure
legends. After 24 h, the inserts were lifted and the cell area
was washed four times to remove floating cells. Photos of
the intersection between the vertical and horizontal
wounds generated by the micro-inserts were taken under
a 10x objective using an iPhone 5 in conjunction with the
SkyLight microscope adapter at 0, 12, and 24 h. Images
were analysed in Image J (National Institutes of Health
(NIH)) to determine the number of cells in the wound
area (calculated as particles per mm2).
Anchorage-independent tumoursphere assay
The ability of colon cancer cell lines to grow as tumour-
spheres in suspension was determined as previously de-
scribed [38]. Briefly, cells were lifted with trypsin, washed
with phosphate-buffered saline (PBS) and passed through
a 40 μM cell strainer (BD Biosciences) to produce a single
cell suspension. Cells were resuspended in anchorage-
independent growth (AIG) medium containing DMEM
with Glutamax™ supplemented with 1% (v/v) PSA, 2%
(v/v) B-27 supplement, 20 ng/ml EGF and bFGF, 4 ng/ml
heparin and 10 μg/ml insulin and seeded into ultralow at-
tachment plates (Corning). Seeding was carried out at a
density of 100 cells per well in a 96-well plate for analysis
of effects of proteins/compounds on tumoursphere forma-
tion and 2000 cells/well in a 96-well plate for collection of
spent media. Tumourspheres were fed every 3 days by the
addition of 50 μl of fresh AIG medium to each well and
processed on Day 7 post seeding.
Chemosensitivity studies
SW480 and SW620 cells were seeded into anchorage-
independent conditions as described above and treated
with either 2 ng/ml TGF-β1, 20 ng/ml Hsp90β, 100 nM
SB431542 or 100 μM novobiocin. After one week,
tumourspheres were dissociated with Accutase® (Sigma-
Aldrich) solution and reseeded into adherent condition in
a 96 well plate at a density of 1.2 x 105 cells/ml, allowed to
adhere overnight and then treated with either 75 μM
5-FU or 550 μM oxaliplatin for 72 h. Cell viability was
assessed compared to an untreated control for each
pre-treatment using a MTT Cell Proliferation kit (Roche)
according to manufacturer’s specifications as previously
described [39].
Statistical analysis
Statistical analysis was carried out using GraphPad
Prism 4.03 software (GraphPad Inc., 2005). A Students
t-test was performed when comparing single data sets
between the two cell lines, while two-way ANOVA with
Bonferroni post-tests were performed where data for a
number of treatments were being compared.
Results
Alterations in the TGF-β pathway in a genetically paired
cell line model
We analysed the status of the TGF-β pathway in the
SW480 cell line derived from a primary colon adenocar-
cinoma and its SW620 lymph node metastasis-derived
counterpart (Fig. 1). Analysis of the spent media of the
cell lines by ELISA revealed that SW480 primary tumour
cells and their SW620 secondary tumour counterparts
secrete similar levels of TGF-β1 (2.50 ± 0.12 vs. 2.12 ±
0.05 ng/ml, Fig. 1a). Analysis of the cell surface receptors
by flow cytometry showed that SW480 cells display
twice the level of TGF-βRII compared to SW620 cells
(Fig. 1b). SW620 cells, on the other hand, display greater
levels of intracellular TGF-β1, specifically in the form of
pre-pro-TGF-β1, compared to SW480 cells (Fig. 1c. Im-
ages cropped from the original full length western blots
provided in Additional file 1). Confocal analysis revealed
that SW620 cells also have a greater proportion of nu-
clear pSmad2/3 than SW480 cells (Fig. 1d), suggesting
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Fig. 1 (See legend on next page.)
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greater pathway activation in the metastatic cell line.
Due to the fact that extracellular Hsp90 has been linked
to the TGF-β pathway and is able to bind both TGF-βRI
and TGF-βRII [31], we also examined the extracellular
levels of Hsp90 in the spent medium of SW480 and
SW620 cells. While we were unable to detect Hsp90α in
the spent media (data not shown), we found that SW620
cells secrete significantly more Hsp90β than SW480 cells
(19.51 ± 4.35 vs. 10.70 ± 3.60 ng/ml, respectively; Fig. 1e).
In addition, we noted that the levels of Hsp90β secreted
by the cells were 5-10 fold higher than those of TGF-β1
(Fig. 1a). The intracellular levels of both cytoplasmic iso-
forms of Hsp90 did not appear to differ between the two
lines (Fig. 1f ).
Effect of extracellular TGF-β and Hsp90 on adhesion and
migration of SW480 and SW620 cells
We next examined the effect of the TGF-β pathway and
Hsp90 on adhesion and migration in vitro, both of which
are biological processes crucial for metastasis. In par-
ticular it has been reported that changes in the cytoskel-
eton and extracellular matrix proteins as well as weak
adhesions may cause an increase in migration and may
be required for cell motility, revealing that adhesion and
migration are two sides of the same coin in terms of me-
tastasis [40–42]. Our analyses revealed that SW480 cells
displayed a significantly higher level of adhesion com-
pared to SW620 cells after 8 h incubation (A590 values
of 0.91 ± 0.27 vs. 0.58 ± 0.24, respectively; p = 0.0027;
Fig. 2a), while SW620 cells appeared to be nearly
three-fold more migratory than SW480 cells after 24 h
(30.15 ± 12.43 vs. 10.58 ± 1.65 particles per mm2,
respectively; p = 0.0016; Fig. 2b). These opposing trends
between the cell lines stand to reason and lend weight to
the hypothesis that if there is less adhesion of the cells
they are more likely to migrate [40–42]. The migration
results also agree with published in vivo studies where
SW620 cells were found to be more migratory when
injected into mice and analysed for liver metastases
[43]. The decreased adhesion and increased migration
of SW620 cells observed in this study therefore validates
the use of the SW480-SW620 system as an in vitro model
of cancer progression.
The effect of addition or inhibition of TGF-β1 and
Hsp90β on the adhesion of SW480 and SW620 cells was
analysed by normalisation to untreated cells (taken as a
100%) as depicted in Fig. 3. In the assessment of adhe-
sion, migration and AIG of SW480 and SW620, TGF-β1
and Hsp90β were used at 2 and 20 ng/ml, which corre-
sponded to the levels of proteins detected in spent media
(Fig. 1). Treatment with the TGF-βRI inhibitor SB431542
and the C-terminal Hsp90 inhibitor novobiocin was
carried out at 100 nM and 100 μM, respectively, in all
cases, as these concentrations were not toxic to either
cell line (data not shown). Adhesion studies in SW480
cells (Fig. 3a), at 8 h post seeding, revealed that treatment
with TGF-β1 did not significantly affect cell adhesion in
SW480 cells in comparison to the untreated cells (85.90 ±
13.98% vs. 100.00 ± 8.42% adhesion, respectively). Simi-
larly, Hsp90β treatment did not have any effect on the
adhesion of SW480 cells (106.51 ± 13.41% adhesion rela-
tive to control). Treatment with a combination of TGF-β1
and Hsp90β, known to bind the common receptor
TGF-βRI [31], again showed no significant change in
(See figure on previous page.)
Fig. 1 Investigating the status of the canonical TGF-β pathway and levels of Hsp90 in the genetically paired SW480 primary and SW620 secondary
tumour-derived colon cancer cell lines. a The secretion of TGF-β1 by SW480 and SW620 cells was determined by means of an ELISA to quantify
the levels of extracellular TGF-β1 in spent culture medium for a given cell number after 12 h incubation. Data represent the average of three
independent experiments performed in triplicate and error bars indicate the standard error in the mean. b The levels of TGF-βRII receptor
on the cell surface was determined by flow cytometry using a fluorescein isothiocyanate-conjugated antibody. Data was analysed using
FlowJo software and gating carried out according to the IgG1 isotype control. Histograms show a shift in fluorescence for each sample
(black line, unshaded) compared to the isotype control (grey shading) and the percentage of positive events is indicated for each sample.
Data are representative of three independent experiments showing consistent results. c Intracellular levels of TGF-β1 in SW480 and SW620
cells were determined by (i) western blot analysis and compared to a histone loading control. The images are cropped from the full length
western blot provided as Additional file 1. (ii) The normalized levels of pre-pro TGFβ1 from the western blot in (i) were determined by densitometry
using ImageJ and calculated according the histone loading control. AU: arbitrary units. The positive control represents commercially obtained
recombinant human TGFβ1 in its active form. d Activation of the TGF-β canonical pathway was determined by the phosphorylation and
nuclear localization of Smad2/3. SW480 and SW620 cells were stained for pSMAD2/3 and nuclei were stained with Hoescht-33342.
Immunofluorescence was detected using the Zeiss LSM 510 Meta laser scanning confocal microscope and the images analysed using
Axiovision LE 4.7.1 software (Zeiss). (i) The first column shows the level of pSmad2/3 staining in the cells, pseudocoloured to white, while
the second column shows a merged image of the nucleus pseudo-coloured to red and the pSMAD2/3 staining pseudocoloured to green.
The third column shows frequency scattergrams obtained using colocalisation analysis on Image J,. Scale bars represent 20 μm. (ii) Graphs
generated from profiles of the nucleus and pSMAD2/3 within individual cells analysed using Zen Lite Software showing the proportion of
total pSMAD2/3 that is found in the nucleus. In all cases, analyses were performed on triplicate images containing at least 10 cells per image e The
secretion of Hsp90β by SW480 and SW620 cells was quantified by means of an ELISA on spent culture medium after 12 h incubation. The data are
representative of two individual experiments performed in triplicate and showing consistent results. f Whole cell lysates from SW480 and SW620 cells
were analysed for Hsp90α and Hsp90β expression using western blot analysis. Where relevant, data was analysed using GraphPad Prism 4.03 software
with errors bars indicating the standard error in the mean and a students t-test was performed to assess statistical significance. (*p < 0.05, **p < 0.01)
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the adhesion of SW480 cells (89.94 ± 16.93%) compared
to untreated cells. Inhibiting the receptor TGF-βRI with
SB431542, either with or without the addition of ex-
ogenous TGF-β1, also had no significant effect on the
adhesion of SW480 cells (83.44 ± 9.72% and 81.52 ±
8.77%, respectively). On the other hand, when SB431542
treatment was combined with both TGF-β1 and Hsp90β,
this caused a decrease in the adhesion of SW480 (71.80 ±
13.55%) in comparison to the untreated cells, although
this was not significantly different to the effect seen after
treatment with the two proteins TGF-β1 and Hsp90β
alone. The inhibition of Hsp90 by the addition of novobio-
cin caused a significant decrease in the adhesion of
SW480 cells relative to the normalised untreated control
(53.09 ± 4.54%). The addition of exogenous Hsp90β and
TGF-β1 in combination with novobiocin was not able to
overcome the inhibition of total Hsp90 by the drug in
terms of adhesion (56.08 ± 2.19%), although it was ob-
served that this decrease in adhesion was significantly less
than TGF-β1 and Hsp90β treatments alone. Since αvβ6
integrin is known to be linked to the TGF-β pathway as
an alternate TGF-β1 receptor [44], we assessed the effect
Fig. 2 Comparison of adhesion and migration in SW480 and SW620
genetically paired colon cancer cell lines. a Adhesion of SW480 and
SW620 cells was assessed by absorbance at 590 nm (y-axis) of crystal
violet stained adherent cells and a comparison between the adhesion
capability of the cells after 8 h was compared. b A Comparison of
migration capability of SW480 and SW620 cells measuring the cells
occupying the wound area after 0, 12 and 24 represented as normalised
particles per area over 24 h relative to particles at 0 h (calculated using
ImageJ). Graphs are representative of three independent experiments
carried out in triplicate showing consistent results. Error bars indicate
the standard error in the mean A students t-test was performed using
GraphPad Prism 4.03 software to assess statistical significance
where n = 3. (**p < 0.01, ***p < 0.001)
Fig. 3 The effect of addition or inhibition of TGF-β and Hsp90 on
adhesion in the paired SW480 and SW620 colon cancer cell lines.
SW480 a and SW620 b cells were treated with 2 ng/ml TGF-β1,
20 ng/ml Hsp90β, 100 nM SB431542, 100 μM novobiocin and
10 μg/ml αvβ6 integrin blocking antibody (anti- αvβ6) singly or in
combinations as indicated on the x-axis. Absorbance at 590 nm of
crystal violet stained adherent cells was normalized to the untreated
control, given as 100%, and depicted by the solid horizontal line in the
graph, showing the changes in cell adhesion for each treatment. All
graphs are representative of the average of three independent
experiments performed in triplicate and error bars indicate the
standard error in the mean. Statistical analysis was performed
using GraphPad Prism 4.03 software. A two-way analysis of variance
(ANOVA) with Bonferroni post-test was performed and significance
between untreated cells and those after each treatment (indicated by
asterisks) and between particular treatments (indicated by hashes) are
shown (*p < 0.05, **p < 0.01, ***p < 0.001, #p < 0.05, ###p < 0.001,
ns – not significant)
de la Mare et al. BMC Cancer  (2017) 17:202 Page 7 of 16
of inhibition of this integrin on adhesion. We found that
treatment with a blocking antibody against αvβ6 (10 μg/
ml) had no significant effect on the adhesion of SW480
cells on its own (83.29 ± 10.75%), but that the antibody
reversed the decrease in adhesion by TGF-β1, Hsp90β
and SB431542 when combined with these treatments
(100.29 ± 14.04%), in the SW480 cells.
The effect of addition or inhibition of TGF-β and
Hsp90 on adhesion was also assessed in SW620 cells
(Fig. 3b), revealing that, in a number of cases, the
metastasis-derived cell line did not respond in the same
way as the SW480 primary tumour-derived line to these
treatments. We found that, unlike in SW480 cells,
addition of TGF-β1 caused a subtle increase in the adhe-
sion of SW620 cells compared to the untreated control
(119.63 ± 17.16 vs. 100.00 ± 14.30% adhesion). On the
other hand, treatment with Hsp90β caused a significant
increase in adhesion of SW620 cells over the control
(142.99 ± 17.13%, p < 0.01) which was once more not
seen for SW480 cells. Unexpectedly, despite the fact that
they each increased adhesion, treatment with a combin-
ation of TGF-β1 and Hsp90β caused a significant de-
crease in the adhesion of SW620 cells (79.69 ± 4.09%).
This decrease in adhesion of SW620 cells was even
greater when comparing Hsp90β treatment alone to the
combination treatment with TGF-β1 (p < 0.001). As was
the case for SW480 cells, inhibition of TGF-βRI with
SB431542, either with or without the addition of exogen-
ous TGF-β1, did not have a significant effect on the ad-
hesion of SW620 cells in comparison to the untreated
cells (83.55 ± 7.43% and 82.91 ± 5.01%, respectively).
Again, it was only when SB431542 treatment was com-
bined with both TGF-β1 and Hsp90β, that a significant
decrease in the adhesion of the cells was observed
(70.68 ± 5.56%). Similar to the effect seen for SW480
cells, this effect was not significantly different to that
seen after treatment with the two proteins TGF-β1 and
Hsp90β alone. As was the case for SW480 cells, the in-
hibition of Hsp90 by novobiocin caused a marked de-
crease in the adhesion of SW620 cells relative to the
normalised untreated control (56.45 ± 5.35%, p < 0.001).
The addition of exogenous Hsp90β and TGF-β1 in com-
bination with novobiocin was once more not able to over-
come the inhibition of Hsp90 on adhesion (54.53 ± 5.02%).
As for SW480 cells, treatment with a αvβ6 blocking anti-
body had no significant effect on the adhesion of SW620
cells on its own (74.68 ± 10.12%); however, when com-
bined with TGF-β1, Hsp90β and SB431542, the antibody
reversed the decreased adhesion by a combination of the
latter three treatments alone (81.25 ± 7.02%).
Migration analysis was performed and the wound area
covered by cells calculated using ImageJ [particles per
area (mm2)] and normalised to each treatment at 0 h
(given as 1) in each of the two cell lines (Fig. 4a and b).
In this case, statistical analysis was carried out between
treatments at 24 h as this was when the greatest migra-
tion was observed. For the SW480 cells (Fig. 4a), treat-
ment with TGF-β1 alone, Hsp90β alone as well as the
combination of TGF-β1 with Hsp90β, caused no signifi-
cant changes in the migration of the cells relative to the
untreated control (9.26 ± 3.08, 10.72 ± 1.71 and 13.44 ±
2.28, respectively vs. 10.58 ± 1.65 normalised particles
per mm2/NPPM). In contrast to this, the inhibition of
the TGF-βRI using SB431542 caused a two-fold increase
in migration of SW480 cells in comparison to the un-
treated cells (23.93 ± 2.07 NPPM). The effect of addition
Fig. 4 The effect of addition or inhibition of TGF-β and Hsp90 on
migration of the paired SW480 and SW620 colon cancer cell lines.
SW480 a and SW620 b cells were treated with 2 ng/ml TGF-β1,
20 ng/ml Hsp90β, 100 nM SB431542, 100 μM novobiocin and
10 μg/ml αvβ6 integrin blocking antibody (anti- αvβ6) singly or in
combinations as indicated on the x-axis and the effect of such
treatment on migration assessed. All graphs are representative of
the average of three independent experiments performed in triplicate
and error bars indicate the standard error in the mean. Statistical
analysis was performed using GraphPad Prism 4.03 software. A
two-way analysis of variance (ANOVA) with Bonferroni post-test
was performed and significance between untreated cells and those
after each treatment (indicated by asterisks) and between particular
treatments (indicated by hashes) are shown (*p < 0.05, **p < 0.01,
***p < 0.001, ##p < 0.01, ###p < 0.001, ns – not significant)
de la Mare et al. BMC Cancer  (2017) 17:202 Page 8 of 16
of TGF-β1 in combination with SB431542 on migration
(28.67 ± 5.58 NPPM) did not differ significantly to that
of treatment with SB431542 alone, suggesting that the
addition of TGF-β1 was unable to overcome the inhib-
ition of the canonical TGF-β/TGF-βR pathway in these
cells. The addition of both TGF-β1 and Hsp90 with
SB431542 treatment, on the other hand, caused a signifi-
cant three-fold increase compared the untreated cells
(36.18 ± 6.24 NPPM). This treatment was also greatly in-
creased in comparison to the combination TGF-β1 and
Hsp90β treatment (p < 0.001). The effect of the combin-
ation of TGF-β1, Hsp90 and SB431542 on migration, how-
ever, was not significantly different to that of SB431542
treatment alone. Novobiocin treatment caused an increase
in migration in SW480 cells relative to the untreated con-
trol (29.76 ± 25.17 NPPM). The effect on migration of
TGF-β1 and Hsp90β in combination with the novobiocin
(34.25 ± 29.79 NPPM) did not differ significantly in com-
parison to novobiocin treatment alone, suggesting that the
addition of endogenous Hsp90β and TGF-β1 could not
overcome the inhibition of Hsp90 by novobiocin. These
treatments did however cause a substantial increase in
migration, in comparison to the treatment using a com-
bination of only TGF-β1 and Hsp90β (p < 0.01). This
highlights that it is the novobiocin specifically that is
causing the increase in migration. The inhibition of the
αvβ6 integrin with a blocking antibody (10 μg/ml) alone
did not have any effect on the migration of SW480 cells
(11.33 ± 5.20 NPPM), including when TGF-β1, Hsp90β
and SB431542 were added (11.67 ± 1.25 NPPM), effect-
ively returning migration to baseline compared to treat-
ment with TGF-β1, Hsp90β and SB431542 alone. This
suggests that αvβ6 integrin may be an alternate recep-
tor mediating migration in response to a combination
of TGF-β1 and Hsp90β in these cells.
When analysing the migration of SW620 cells (Fig. 4b),
it was found that treatment with either TGF-β1 or Hsp90β
caused minor decreases in the migration of these cells in
comparison to the untreated cells (11.46 ± 2.53 and
17.30 ± 4.66 vs. 30.15 ± 12.43 NPPM, respectively). On
the other hand, treatment with a combination of TGF-β1
and Hsp90β caused a statistically significant two-fold
increase in migration of SW620 cells in comparison to
untreated cells (61.21 ± 16.24 NPPM). This increase in
migration of SW620 cells caused by the combination
treatment was significantly higher than either TGF-β1
or Hsp90β treatment alone (p < 0.001 and p < 0.01, re-
spectively). Unlike in SW480 cells, SB431542 treatment
alone did not cause a significant change in the migra-
tion of SW620 cells relative to the untreated control
(43.73 ± 17.25 NPPM). However, similarly to SW480
cells, treatment of SW620 cells with a combination of
SB431542 and TGF-β1 as well as a combination of
SB431542, TGF-β1 and Hsp90β caused a substantial
increase in migration (90.50 ± 17.03 and 77.28 ± 16.89
NPPM, respectively). This increase in migration was
however not significantly different to the combination
treatment of TGF-β1 and Hsp90β alone. These data
suggest that the pro-migratory effect of the combination
of TGF-β1 and Hsp90β is not disrupted by inhibition of
the receptor, suggesting that the canonical pathway is not
being used. Treatment with novobiocin alone and in com-
bination with TGF-β1 and Hsp90β had no significant ef-
fect on the migration of SW620 cells relative to the
untreated control (37.27 ± 25.75 and 42.15 ± 1.82 NPPM,
respectively), unlike in SW480 where the drug caused a
substantial increase in migration. While disruption of
αvβ6 integrin using a blocking antibody did not cause any
change in the migration of SW620 cells (28.98 ± 16.34
NPPM), this was able to overcome the stimulation of
migration caused by a combination of TGF-β1, Hsp90β
and SB431542, (31.71 ± 12.16 NPPM for treatment with
αvβ6 integrin + TGF-β1 +Hsp90β + SB- 431542), thereby
returning migration to a level comparable with untreated
cells. This trend was the same as that observed in SW480
cells.
Effect of extracellular TGF-β and Hsp90 on anchorage-
independent growth (AIG) of SW480 and SW620 cells
Since the ability of malignant cells to survive and grow
anchorage-independently is a requirement for metastasis,
we investigated the secretion of and response to TGF-β1
and Hsp90β of the paired colon cancer cell lines under
such conditions. The cell lines were grown in suspension
as well defined three-dimensional structures known as
tumourspheres, with both cell lines forming spheres of
similar morphologies and size (Fig. 5a). When comparing
the secretion of TGF-β1 and Hsp90β by these tumour-
spheres (Fig. 5b) we found that SW480 tumourspheres
produced much higher levels (p < 0.001) of both proteins
in the spent media compared to SW620 tumourspheres
(TGF-β1: 11.68 ± 1.03 vs. 5.85 ± 2.35 ng/ml, respectively;
Hsp90β: 81.28 ± 0.43 vs. 0.10 ± 0.23, respectively) as well
as to either cell line grown adherently (TGF-β1: 2.97 ±
0.05 ng/ml in SW480, 2.52 ± 0.04 ng/ml in SW620;
Hsp90β: 0.44 ± 0.18 ng/ml in SW480, 8.96 ± 0.66, in
SW620 cells).
We next assessed the effect of addition or inhibition of
TGF-β1 and Hsp90β on the ability of both cell lines to
form tumourspheres as a measure of anchorage-
independent growth (Fig. 5c). Sphere forming efficiency
(SFE) was defined as the percentage of the total number
of cells seeded that are able to form tumourspheres after
7 days and this was normalized to that of untreated cells
for each cell line (taken as 100%). In SW480 cells
(Fig. 5c), we found that addition of either TGF-β1 or
Hsp90β alone caused a statistically significant decrease
in SFE compared to untreated cells (72.00 ± 9.60 and
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Fig. 5 Investigation of the role of TGF-β and Hsp90 in anchorage-independent growth of SW480 and SW620 cells. a Photograph of tumourspheres
formed by SW480 (i) and SW620 (ii) cells taken under a light microscope at 100x magnification. Scale bars indicate 100 μm. b Comparison of TGF-β1
and Hsp90β secretion by SW480 primary and SW620 secondary tumour-derived cells grown adherently and in suspension using a DuoSet ELISA kit (R
and D systems) and sandwich ELISA method, respectively. Data shown are representative of three individual experiments carried out in triplicate and
showing consistent results. Statistical significance was assessed using GraphPad Prism 4.03 software by means of a two-way analysis of variance
(ANOVA) with Bonferroni post-test where n = 3. Comparisons in terms of the levels of proteins between adherent cells and tumoursphere (within cell
lines) is indicated by asterisks (*), while comparisons between cell lines is indicated by hashes (#). c and d Analysis of the effect of addition or inhibition
of TGF-β or Hsp90 on tumoursphere formation. Sphere forming efficiency (percentage of the total number of cells seeded that are able to
form tumourspheres after 7 days) of SW480 c and SW620 cells d was normalized to that of untreated cells for each cell line (taken as 100%).
Error bars indicate the standard error in the mean where n = 4. Statistical significance was assessed using GraphPad Prism 4.03 software by
means of a two-way analysis of variance (ANOVA) with Bonferroni post-test and significance between untreated cells and those after each
treatment (indicated by asterisks) as well as between particular treatments (indicated by hashes) are shown (*p < 0.05, **p < 0.01, #p < 0.05,
##p < 0.01, ###p < 0.001)
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74.13 ± 2.44%, respectively vs. 100.00 ± 6.40%; p < 0.001
in each case). On the other hand, a combination of
Hsp90β and TGF-β1 led to a significant increase in SFE
(108.27 ± 6.65%) relative to SW480 cells treated with ei-
ther protein alone (p < 0.05 for TGF-β1, p < 0.01 for
Hsp90β), returning SFE to the level observed in un-
treated cells. While the addition of SB431542 alone had
no significant effect on SFE in these cells (94.93 ±
1.85%), the inhibitor was able to reverse the effect of
TGF-β1 on SFE (107.73 ± 6.66%). Interestingly, the com-
bination of TGF-β1, Hsp90β and SB431542 caused a
marked increase in SFE relative to the untreated control
(111.47 ± 5.11%, p < 0.01). An even greater increase in
SFE was observed for cells treated with the novobiocin
(137.07 ± 6.06%, p < 0.001), and this was not affected by
the addition of both TGF-β1 and Hsp90β (138.67 ±
22.19%). Since αVβ6 integrin is an alternate receptor in
the TGF-β machinery, we assessed the effect of a block-
ing antibody against this integrin on SFE. While the
antibody alone had no effect on SFE of SW480 cells
(99.20 ± 9.99%), it was able to reverse the increase in
SFE caused by the combination of TGF-β1, Hsp90β and
SB431542 (82.66 ± 19.29% for cell treated with the αVβ6
integrin antibody, TGF-β1, Hsp90β and SB431542).
In terms of anchorage-independent growth in the
SW620 cell line (Fig. 5d), it was clear that these cells
responded very differently not only to addition but
also inhibition of TGF-β and Hsp90 compared to the
SW480 line and that, in general, these treatments had
less of an impact on SFE in SW620 cells. In particular
we found that, unlike in SW480 cells, anchorage-
independent growth in these cells was not affected by
the addition of TGF-β1 (SFE of 97.11 ± 6.00% in
treated cells vs. 100.00 ± 11.69% in untreated cells).
Hsp90, on the other hand, caused a significant in-
crease in SFE in SW620 cells (129.87 ± 5.21%), a trend
which is opposite to that observed in SW480 cells.
Interestingly, this increase in SFE upon Hsp90 treat-
ment was reversed when combined with TGF-β1
(84.39 ± 2.00% SFE). Treatment with SB431542 had no
real effect on tumoursphere formation either alone
(90.56 ± 8.98% SFE) or when combined with TGF-β1
alone (108.67 ± 2.00%) or TGF-β1 with Hsp90β
(105.20 ± 4.00%). Unexpectedly, inhibition with novo-
biocin also increased AIG in SW620 cells (120.23 ±
8.73%) in the same manner as Hsp90β addition but
this effect was no longer significant when the drug
was combined with TGF-β1 and Hsp90β (119.85 ±
10.74%). It is important to note however that this in-
hibitor is not specific to the Hsp90β isoform or extra-
cellular Hsp90. An αVβ6 integrin blocking antibody
had no effect on SFE of SW620 cells either alone
(96.34 ± 5.82%), or when combined with TGF-β1,
Hsp90β and SB 431542 (91.71 ± 5.95%).
Effect of Hsp90 and TGF-β1 pre-treatment under AIG
conditions on chemosensitivity to colon cancer
chemotherapeutics
We assessed the effect of pre-treatment under AIG con-
ditions by either addition or inhibition of TGF-β1 and
Hsp90 on chemosensitivity of SW480 and SW620 cells
to oxaliplatin and 5-FU (Fig. 6). Pre-treatment was car-
ried out under AIG conditions since this has been dem-
onstrated to enrich for cancer stem cells (CSC) by
ourselves and others [38, 45] and this sub-population is
reportedly resistant to traditional chemotherapeutic
agents due to the overexpression of several drug trans-
porters [46]. The chemosensitivity assay used high con-
centrations of the colon cancer drugs as previously
described [47], namely 550 μM 5-FU and 75 μM oxali-
platin, in order to see any chemoresistance which may
result from the various pre-treatments. In the assay, pre-
treatment with TGF-β1, Hsp90, SB 431542 or novobio-
cin was carried out upon seeding into AIG conditions.
The resultant tumourspheres after 7 days of culture were
dissociated and seeded into regular culture conditions,
allowed to adhere overnight, and then treated with ve-
hicle control (representing “untreated” cells), 5-FU or
oxaliplatin. For each pre-treatment, viability was calcu-
lated relative to its own vehicle-treated control (taken as
100%). A comparison was also made with untreated cells
(i.e. not pre-treated) that had previously either been
grown adherently (first bar in each graph of Fig. 6) or
been cultured as tumourspheres and then dissociated
(second bar in each graph of Fig. 6). In each case, statis-
tical significance was assessed in comparison to cells with
had been cultured as tumourspheres but not pre-treated
(second bar in each graph). We report that pre-culturing
as tumourspheres under AIG conditions appears to infer
chemoresistance of SW480 primary tumour cells to 5-FU
(47.16 ± 0.54% survival for tumoursphere-derived un-
treated cells vs. 11.27 ± 2.64% for adherently cultured un-
treated cells, Fig. 6ai). This was expected since a previous
study by [47] reported that colon CSC are 60-fold more
resistant to 5-FU. In terms of pre-treatment during AIG,
we found that TGF-β1, Hsp90β, SB431542 and novobiocin
all significantly increased chemosensitivity of SW480 cells
to 5-FU (26.04 ± 1.30%, 15.31 ± 3.15%, 16.79 ± 1.96% and
39.20 ± 0.17% survival, respectively, Fig. 6ai).
Converse to that observed for SW480 cells, pre-culture
as tumourspheres rendered SW620 cells significantly
more sensitive to 5-FU (22.81 ± 2.17 for tumoursphere-
derived cells vs. 31.53 ± 1.94% for adherent cells, Fig. 6aii).
On the other hand, similar trends were noted in the
SW620 cells compared to the SW480 cells in terms of
the effect of pre-treatment with TGF-β1, Hsp90β and
SB431542, though the resultant chemosensitivity was less
pronounced (19.63 ± 0.45%, 15.69 ± 1.38% and 17.04 ±
0.85%, respectively, Fig. 6aii). The major difference between
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the cell lines in terms of pre-treatment was the effect of
novobiocin which, unlike in SW480 cells, significantly
decreased the sensitivity of SW620 cells to 5-FU (38.36 ±
3.48% survival).
We report that, unlike for 5-FU, AIG pre-culture did
not significantly influence the chemosensitivity of SW480
cells to oxaliplatin (37.16 ± 2.30% survival in tumoursphere-
derived cells vs. 36.35 ± 3.24% in adherent cells, Fig. 6bi).
This was unexpected since [47] reported that colon CSC
are 15-fold more resistant to oxaliplatin than bulk colon
tumour cells. The various pre-treatments had less of an ef-
fect on chemosensitivity in general of SW480 cells to oxali-
platin compared to 5-FU. In particular, pre-treatment with
TGF-β1 and SB431542 did not influence chemosensitivity
to oxaliplatin (37.72 ± 1.82%, 38.74 ± 2.02% survival, re-
spectively) while Hsp90β and novobiocin pre-treatment
rendered SW480 cells significantly more resistant to the
drug (63.00 ± 1.63% and 82.91 ± 4.90% survival, respectively,
Fig. 6bi), the latter effect being opposite to that observed
for 5-FU.
In the case of SW620 cells, as for SW480 cells AIG
pre-culture did not influence the chemosensitivity of the
cells to oxaliplatin (67.22 ± 3.56% in tumoursphere-
derived cells vs. 59.73 ± 2.42% in adherent cells, Fig. 6bii).
In terms of pre-treatment, only SB431542 treatment had
a significant effect on sensitivity to oxaliplatin, causing a
slight increase in sensitivity of SW620 cells (55.09 ±
5.03% survival), with no significant effects on chemosen-
sitivity noted for pre-treatment with TGF-β1, Hsp90β or
novobiocin (62.93 ± 3.62%, 68.17 ± 2.35% and 82.91 ±
4.90% survival, respectively, Fig. 6bii).
Discussion
The role of TGF-β in cancer progression is notoriously
duplicitous, with the chemokine acting as a tumour sup-
pressor in the early stages of carcinogenesis but a pro-
moter of metastasis in the later stages [14]. The SW480/
SW620 cell lines represent an in vitro model for the
changes associated with the acquisition of a metastatic
phenotype since the cell lines are derived from a primary
adenocarcinoma of the colon (SW480) and its lymph
node metastasis (SW620) from the same patient [48]. It
was therefore interesting to observe the levels of the
various components of the TGF-β pathway in these cells.
Fig. 6 Effect of pre-treatment of paired colon cancer cell lines by the addition or inhibition of TGF-β or Hsp90 under anchorage independent
conditions on subsequent sensitivity to colon chemotherapeutics. SW480 (i) and SW620 (ii) cells were treated with either 2 ng/ml TGF-β1, 20 ng/ml
Hsp90β, 100 nM SB431542 or 100 μM novobiocin upon seeding in a tumoursphere assay. After 7 days, tumourspheres were reseeded into regular
adherent growth conditions and treated with 75 μM 5-fluorouracil a or 550 μM oxaliplatin b for 72 h. Cell viability was assessed compared to an
untreated control for each pre-treatment using a MTT Cell Proliferation kit. Data are representative of two individual experiments carried out in triplicate
and showing consistent results. Statistical significance was assessed by means of a two-way analysis of variance (ANOVA) with Bonferroni post-tests
relative to the non-pre-treated control using GraphPad prism where n = 3 (*p < 0.05, **p < 0.01)
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The majority of studies regarding the role of the TGF-β
in colon cancer reported in the literature have been car-
ried out in resected tumours and their respective metas-
tases and ours is thus the first study to our knowledge
comparing the TGF-β1 machinery in paired colon can-
cer cell lines. We report that there are key differences in
the TGF-β1 pathway between the SW480 and SW620
cell lines. In particular, the SW480 primary tumour-
derived line displays a higher level of the receptor TGF-
βRII, while the SW620 secondary tumour-derived line
displays higher intracellular TGF-βI. These findings
agree with published reports in that a low level of TGF-
βR (both TGF-βRI and TGF- βRII) has been demonstrated
to correlate with disease progression [49] and high levels
of TGF-β1 in colon cancer have been correlated with a
poor disease prognosis in a clinical setting, specifically in-
creasing metastasis and general invasiveness [50, 51]. Fur-
thermore, the increase in nuclear pSmad2/3 observed in
SW620 cells in this study suggested that the pathway may
be constitutively active in the metastasis-derived line.
Since TGF-β1 and Hsp90β are able to bind the same
receptors [31], we explored in detail the consequences of
a synergy between these processes on adhesion, migra-
tion and AIG. We report that exogenous TGF-β1 has no
effect on the level of adhesion or migration in either cell
line but that the addition of Hsp90β increases the adhe-
sion of SW620 secondary tumour but not SW480 pri-
mary tumour-derived cells, without affecting migration.
The finding that TGF-β1 has no effect on migration was
unexpected since a number of studies have suggested
that the protein increases migration, in particular in lung
cancer [52], hepatocellular carcinoma [32] and breast
cancer cell lines [33] using a range of techniques. Simi-
larly, extracellular Hsp90 has been shown to stimulate
migration in glioblastoma (A-172) and fibrosarcoma
(HT1080) cell lines [53], which was not the case in our
study. Interestingly, we found that the effect of addition
of TGF-β1 and Hsp90β on AIG is opposite in the two
cell lines in that the exogenous addition of each of these
proteins inhibits the formation of tumourspheres in
SW480 primary tumour-derived cells, but has either no
effect (in the case of TGF-β1) or stimulates tumour-
sphere formation (in the case of Hsp90β) in the SW620
metastasis-derived line. Overall, the latter findings sug-
gest that cells in a primary tumour may respond differ-
ently to cytokine signalling by TGF-β1 and Hsp90β
compared to cells in a secondary tumour in terms of meta-
static behaviour, in particular adhesion, migration and AIG.
In contrast to the effect of the proteins alone, we
found that treatment with a combination of TGF-β1 and
Hsp90β caused a significant decrease in the adhesion
and corresponding increase in migration of SW620 cells
while having no effect on SW480 cells. In addition, we
noted that the effect of TGF-β1 and Hsp90β alone on
AIG is opposite to that when combined in the SW480
cell line. These findings led us to suspect a synergy
between TGF-β1 and Hsp90β in mediating adhesion,
migration and AIG, which has not previously been
suggested in the literature.
We note that, in SW480 cells, the greatest effect on
adhesion in the cell lines was caused by treatment with
the Hsp90 inhibitor novobiocin, which both alone and in
combination with TGF-β1 and Hsp90β, decreased the
level of adhesion in both cell lines, suggesting that it is
Hsp90β and not TGF-β1 which plays the more import-
ant role in regulating adhesion in these cancer cells.
Conversely, in terms of migration, it appears that it is
TGF-βRI which is the major regulatory protein, particu-
larly in SW480 cells as SB431542 treatment alone, in
combination with TGF-β1 or with TGF-β1 and Hsp90β
increases migration in SW480 cells. On the other hand,
in SW620 cells this effect is not seen with the drug alone
but only when it is combined with TGF-β1 or with
TGF-β1 and Hsp90β, suggesting that these cells do not
require inhibition of the canonical TGF-β pathway in
order to stimulate migration in the presence of a com-
bination of TGF-β1 and Hsp90β as evidenced by the
fact that these two proteins alone are able to achieve
this. This would allow them to respond more effectively
to the pro-metastasis stimulus of a combination of Hsp90β
and TGF-β1 and this could account for the increased
migratory capacity of these cells. Contrary to the findings
in our study, previous reports have demonstrated that
SB431542 inhibits lung (A549) and glioma (D54MG)
cancer cell migration [52, 54], in particular that the
compound is able to reverse the increased migration
associated with TGF-β1 treatment of A549 cells [52]. It
is unclear whether these differences are due to the dif-
ferent migration assays used, in that our study assessed
linear migration via a wound healing assay whereas
Halder et al and Hjelmeland et al [52, 54] used a trans-
well assay, or whether the differences reflect the differ-
ent roles of the TGF-βRI-mediated pathway in cancer
cell lines of different origins.
The most intriguing finding in this study was that a
combination of TGF-β1, Hsp90β and the TGF-βRI in-
hibitor SB431542 markedly decreased the level of adhe-
sion, while increasing migration and AIG of both
SW480 and SW620 cells, revealing a clear trend towards
metastatic behaviour of the cells in response to this
combination of treatments. These findings suggested
that an alternate receptor (in place of TGF-βRI) was
acting in the presence of TGF-β1 when the canonical
TGF-β1 pathway was inhibited by treatment with
SB431542. We considered αvβ6 integrin as a potential
candidate for this alternate receptor as signalling by
TGF-β1 via αvβ6 integrin has been demonstrated in a
range of carcinoma cell lines [44]. Indeed, we found
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that treatment with a blocking antibody against αvβ6
integrin had no effect on adhesion, migration or AIG of
either cell line on its own, but that the antibody reversed
the decrease in adhesion and increase in migration and
anchorage-independent growth upon combination
treatment with TGF-β1, Hsp90β and SB431542. Taken
together, this suggests a role for αvβ6 integrin in medi-
ating this unique effect of the two proteins on these
cellular processes.
Finally, we examined a potential role for TGF-β1 and/or
Hsp90β in conferring chemoresistance of the paired
SW480 and SW620 colon cell lines to the chemothera-
peutics 5-FU and oxaliplatin. Pre-treatment was carried
out under AIG conditions since this assay is known to en-
rich for CSC [45], a sub-population that has been sug-
gested to be resistant to traditional chemotherapeutics
[46]. Indeed, culturing of SW480 cells under AIG condi-
tions rendered them more resistant to 5-FU, although this
trend was not observed for either SW620 cells in terms of
sensitivity to 5-FU or for either SW480 or SW620 cells in
terms of sensitivity to oxaliplatin. In addition, we report
that, although the effect of TGF-β1 and Hsp90β on
tumoursphere forming ability differs greatly between the
SW480 and SW620 cells, the effect of pre-treatment of
these cells under AIG conditions by the addition or inhib-
ition of these proteins on chemosensitivity to 5-FU and
oxaliplatin were relatively similar overall. The major ex-
ception to this was in the effect of novobiocin pre-
treatment, which differed greatly between the cell lines
and the two drugs tested. Importantly, from a therapeutic
viewpoint, none of the pre-treatments increased chemo-
sensitivity of the colon cancer cell lines to either 5-FU or
oxaliplatin to below the level of untreated cells cultured
adherently.
Conclusions
In summary, we report that there are key differences in
the TGF-β1 pathway between the SW480 cell line de-
rived from a primary colon adenocarcinoma and its
SW620 lymph node metastasis-derived counterpart, in
particular that the pathway may be constitutively active
in the metastasis.
We suggest that an alternate pathway to the canonical
TGF-βR1/II-Smad2/3 (Fig. 7a) may be operating in the
cells when TGF-β1 occurs together with Hsp90β (Fig. 7b)
and that this pathway promotes metastatic behaviour in
terms of adhesion, migration and AIG when the canon-
ical TGF-β pathway is inhibited, particularly in SW480
cells, which are a model for early stage colon cancer. In
all cases, αvβ6 integrin was identified as the potential al-
ternate receptor for TGF-β1 mediating these metastatic
processes in the presence of Hsp90β. Interestingly, in
Fig. 7 Model describing the effect of a synergy between extracellular TGF-β1 and Hsp90β on downstream signalling in colon cancer cells. a In
the presence of TGF-β1 alone, binding to the heterotetrameric TGF-βRI/II receptor complex triggers phosphorylation of Smad2/3 and subsequent
activation of Smad4, whereupon the complex moves into the nucleus and triggers transcription of canonical Smad-responsive genes such as
VEGF (tumour promoting) and Fas (tumour suppressing). b In the presence of both TGF-β1 and Hsp90β in the extracellular space, when binding
of TGF-β1 to the TGF-βRI/II receptor complex is inhibited using SB431542, TGF-β1 and Hsp90β instead bind to αvβ6 integrin, triggering as yet
unknown downstream non-Smad signalling pathways, culminating in the transcription of genes which promote metastatic behaviours including
migration and anchorage-independent growth (AIG). This alternate pathway does not require inhibition of TGF-βRI/II and is constitutively active in
SW620 cells, which represent a later stage of colon cancer compared to SW480 cells
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the case of migration, it would appear that the alternate
TGF-β1 pathway (Fig. 7b) is already active in SW620
cells without requiring inhibition by SB431542 in these
cells which represent a later stage of the disease. If this
is the case, then it is feasible that the activation of such
a pathway which allows for an increased ability to re-
spond to the pro-metastasis signalling of a combination
of TGF-β1 and Hsp90β could be responsible for the
spread of cancer from the primary tumour to the lymph
node in the patient from whom the genetically paired
cell lines were derived. This study therefore suggests a
potential biological relevance for the previously pro-
posed role of Hsp90 in regulating TGF-β signalling.
Additional file
Additional file 1: Western blot analysis of the intracellular levels of
TGF-β1 in SW480 and SW620 cells compared to a histone loading control.
Full-length versions of the western blots shown in Fig. 1c. A) SW480 and
SW620 whole cell lysates were probed for TGF-β1 using mouse anti-human
TGF-β1 (sc-65378, Santa Cruz). Purified recombinant TGF-β1 (Biolegend) in
its acid-activated form was included as a positive control (+). B) The
membrane was reprobed for histone as a loading control using rabbit
anti-human histone (9715 L, Cell Signalling Technologies). (TIF 1216 kb)
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